{"id":"viagra","rwe":[],"_fda":{"id":"31f67f3f-1e54-b8f7-e063-6294a90ae30e","set_id":"00ee09dd-2de0-4dc4-85f6-b51ed6eabd5b","openfda":{"upc":["0372789404301"],"unii":["BW9B0ZE037"],"route":["ORAL"],"rxcui":["314228"],"spl_id":["31f67f3f-1e54-b8f7-e063-6294a90ae30e"],"brand_name":["SILDENAFIL CITRATE"],"spl_set_id":["00ee09dd-2de0-4dc4-85f6-b51ed6eabd5b"],"package_ndc":["72789-404-30","72789-404-90"],"product_ndc":["72789-404"],"generic_name":["SILDENAFIL CITRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SILDENAFIL CITRATE"],"manufacturer_name":["PD-Rx Pharmaceuticals, Inc."],"application_number":["ANDA209302"],"original_packager_product_ndc":["75834-272"]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary Sildenafil is not indicated for use in females. There are no data with the use of sildenafil in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m 2 basis ( see Data ). Data Animal Data No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m 2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m 2 basis in a 50 kg subject."],"overdosage":["10 OVERDOSAGE In studies with healthy volunteers of single doses up to 800 mg, adverse reactions were similar to those seen at lower doses but incidence rates and severities were increased. In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine."],"description":["11 DESCRIPTION Sildenafil tablets, USP, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate, is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H -pyrazolo[4,3- d ]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: Sildenafil citrate, USP is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. Sildenafil tablets USP are formulated as pale blue to blue film-coated tablets equivalent to 25 mg, 50 mg and 100 mg of sildenafil for oral administration. Sildenafil tablets 50 mg and 100 mg are caplet shaped whereas sildenafil tablets 25 mg are round shaped. In addition to the active ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dicalcium phosphate anhydrous, FD&C Blue # 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin. sildenafil-citrate-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Sildenafil tablets USP are supplied as pale blue to blue, caplet shaped film-coated tablets containing sildenafil citrate equivalent to the nominally indicated amount of sildenafil as follows: For 25 mg - Pale blue to blue, round film-coated tablets, debossed with “25” on one side and “SL” on other side. NDC 72789-404-30 Bottles of 30 Tablets NDC 72789-404-90 Bottles of 90 Tablets Recommended Storage: Store at 25°C (77°F); excursions permitted within 15-30°C (59-86°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [ see Clinical Pharmacology (12.3) ]. Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [ see Clinical Pharmacology (12.3) ]. Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects. However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure [ see Dosage and Administration (2.5) ]."],"pediatric_use":["8.4 Pediatric Use Sildenafil is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients."],"effective_time":"20250404","clinical_studies":["14 CLINICAL STUDIES In clinical studies, sildenafil was assessed for its effect on the ability of men with erectile dysfunction (ED) to engage in sexual activity and in many cases specifically on the ability to achieve and maintain an erection sufficient for satisfactory sexual activity. Sildenafil was evaluated primarily at doses of 25 mg, 50 mg and 100 mg in 21 randomized, double-blind, placebo-controlled trials of up to 6 months in duration, using a variety of study designs (fixed dose, titration, parallel, crossover). Sildenafil was administered to more than 3,000 patients aged 19 to 87 years, with ED of various etiologies (organic, psychogenic, mixed) with a mean duration of 5 years. Sildenafil demonstrated statistically significant improvement compared to placebo in all 21 studies. The studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with placebo. Efficacy Endpoints in Controlled Clinical Studies The effectiveness of sildenafil was evaluated in most studies using several assessment instruments. The primary measure in the principal studies was a sexual function questionnaire (the International Index of Erectile Function-IIEF) administered during a 4-week treatment-free run-in period, at baseline, at follow-up visits, and at the end of double-blind, placebo-controlled, at-home treatment. Two of the questions from the IIEF served as primary study endpoints; categorical responses were elicited to questions about (1) the ability to achieve erections sufficient for sexual intercourse and (2) the maintenance of erections after penetration. The patient addressed both questions at the final visit for the last 4 weeks of the study. The possible categorical responses to these questions were (0) no attempted intercourse, (1) never or almost never, (2) a few times, (3) sometimes, (4) most times, and (5) almost always or always. Also collected as part of the IIEF was information about other aspects of sexual function, including information on erectile function, orgasm, desire, satisfaction with intercourse, and overall sexual satisfaction. Sexual function data were also recorded by patients in a daily diary. In addition, patients were asked a global efficacy question and an optional partner questionnaire was administered. Efficacy Results from Controlled Clinical Studies The effect on one of the major end points, maintenance of erections after penetration, is shown in Figure 6, for the pooled results of 5 fixed-dose, dose-response studies of greater than one month duration, showing response according to baseline function. Results with all doses have been pooled, but scores showed greater improvement at the 50 and 100 mg doses than at 25 mg. The pattern of responses was similar for the other principal question, the ability to achieve an erection sufficient for intercourse. The titration studies, in which most patients received 100 mg, showed similar results. Figure 6 shows that regardless of the baseline levels of function, subsequent function in patients treated with sildenafil was better than that seen in patients treated with placebo. At the same time, on-treatment function was better in treated patients who were less impaired at baseline. Figure 6. Effect of sildenafil and Placebo on Maintenance of Erection by Baseline Score. The frequency of patients reporting improvement of erections in response to a global question in four of the randomized, double-blind, parallel, placebo-controlled fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 7. These patients had erectile dysfunction at baseline that was characterized by median categorical scores of 2 (a few times) on principal IIEF questions. Erectile dysfunction was attributed to organic (58%; generally not characterized, but including diabetes and excluding spinal cord injury), psychogenic (17%), or mixed (24%) etiologies. Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 mg and 100 mg of sildenafil, respectively, reported an improvement in their erections, compared to 24% on placebo. In the titration studies (n=644) (with most patients eventually receiving 100 mg), results were similar. Overall treatment p<0.0001 Figure 7. Percentage of Patients Reporting an Improvement in Erections. The patients in studies had varying degrees of ED. One-third to one-half of the subjects in these studies reported successful intercourse at least once during a 4-week, treatment-free run-in period. In many of the studies, of both fixed dose and titration designs, daily diaries were kept by patients. In these studies, involving about 1600 patients, analyses of patient diaries showed no effect of sildenafil on rates of attempted intercourse (about 2 per week), but there was clear treatment-related improvement in sexual function: per patient weekly success rates averaged 1.3 on 50-100 mg of sildenafil vs 0.4 on placebo; similarly, group mean success rates (total successes divided by total attempts) were about 66% on sildenafil vs about 20% on placebo. During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label studies, few patients withdrew from active treatment for any reason, including lack of effectiveness. At the end of the long-term study, 88% of patients reported that sildenafil improved their erections. Men with untreated ED had relatively low baseline scores for all aspects of sexual function measured (again using a 5-point scale) in the IIEF. Sildenafil improved these aspects of sexual function: frequency, firmness and maintenance of erections; frequency of orgasm; frequency and level of desire; frequency, satisfaction and enjoyment of intercourse; and overall relationship satisfaction. One randomized, double-blind, flexible-dose, placebo-controlled study included only patients with erectile dysfunction attributed to complications of diabetes mellitus (n=268). As in the other titration studies, patients were started on 50 mg and allowed to adjust the dose up to 100 mg or down to 25 mg of sildenafil; all patients, however, were receiving 50 mg or 100 mg at the end of the study. There were highly statistically significant improvements on the two principal IIEF questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) on sildenafil compared to placebo. On a global improvement question, 57% of sildenafil patients reported improved erections versus 10% on placebo. Diary data indicated that on sildenafil, 48% of intercourse attempts were successful versus 12% on placebo. One randomized, double-blind, placebo-controlled, crossover, flexible-dose (up to 100 mg) study of patients with erectile dysfunction resulting from spinal cord injury (n=178) was conducted. The changes from baseline in scoring on the two end point questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of sildenafil. On a global improvement question, 83% of patients reported improved erections on sildenafil versus 12% on placebo. Diary data indicated that on sildenafil, 59% of attempts at sexual intercourse were successful compared to 13% on placebo. Across all trials, sildenafil improved the erections of 43% of radical prostatectomy patients compared to 15% on placebo. Subgroup analyses of responses to a global improvement question in patients with psychogenic etiology in two fixed-dose studies (total n=179) and two titration studies (total n=149) showed 84% of sildenafil patients reported improvement in erections compared with 26% of placebo. The changes from baseline in scoring on the two end point questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of sildenafil. Diary data in two of the studies (n=178) showed rates of successful intercourse per attempt of 70% for sildenafil and 29% for placebo. Efficacy Results in Subpopulations in Controlled Clinical Studies A review of population subgroups demonstrated efficacy regardless of baseline severity, etiology, race and age. Sildenafil was effective in a broad range of ED patients, including those with a history of coronary artery disease, hypertension, other cardiac disease, peripheral vascular disease, diabetes mellitus, depression, coronary artery bypass graft (CABG), radical prostatectomy, transurethral resection of the prostate (TURP) and spinal cord injury, and in patients taking antidepressants/antipsychotics and anti-hypertensives/diuretics. sildenafil-citrate-figure-6 sildenafil-citrate-figure-7"],"pharmacodynamics":["12.2 Pharmacodynamics Effects of sildenafil on Erectile Response: In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (RigiScan ® ), after sildenafil administration compared with placebo. Most studies assessed the efficacy of sildenafil approximately 60 minutes post dose. The erectile response, as assessed by RigiScan ® , generally increased with increasing sildenafil dose and plasma concentration. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours. Effects of sildenafil on Blood Pressure: Single oral doses of sildenafil (100 mg) administered to healthy volunteers produced decreases in sitting blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8.3/5.3 mmHg). The decrease in sitting blood pressure was most notable approximately 1-2 hours after dosing, and was not different than placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [ see Contraindications (4.1) ]. Effects of sildenafil on Blood Pressure When Nitroglycerin is Subsequently Administered: Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL). In the following patients: age >65 years, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of erythromycin or strong CYP3A4 inhibitors, plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [ see Contraindications (4.1) ]. Effects of sildenafil on Blood Pressure When Co-administered with Alpha-Blockers: Three double-blind, placebo-controlled, randomized, two-way crossover studies were conducted to assess the interaction of sildenafil with doxazosin, an alpha-adrenergic blocking agent. Study 1: Sildenafil with Doxazosin In the first study, a single oral dose of sildenafil 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH). Following at least 14 consecutive daily doses of doxazosin, sildenafil 100 mg or matching placebo was administered simultaneously with doxazosin. Following a review of the data from these first 4 subjects (details provided below), the sildenafil dose was reduced to 25 mg. Thereafter, 17 subjects were treated with sildenafil 25 mg or matching placebo in combination with doxazosin 4 mg (15 subjects) or doxazosin 8 mg (2 subjects). The mean subject age was 66.5 years. For the 17 subjects who received sildenafil 25 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg) sildenafil citrate 25 mg Supine 7.4 (-0.9, 15.7) Standing 6.0 (-0.8, 12.8) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 25 mg sildenafil or matching placebo are shown in Figure 2. Blood pressure was measured immediately pre-dose and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours after sildenafil or matching placebo. Outliers were defined as subjects with a standing systolic blood pressure of <85 mmHg or a decrease from baseline in standing systolic blood pressure of >30 mmHg at one or more timepoints. There were no subjects treated with sildenafil 25 mg who had a standing SBP < 85mmHg. There were three subjects with a decrease from baseline in standing systolic BP >30mmHg following sildenafil 25 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and two subjects with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil and placebo. No severe adverse events potentially related to blood pressure effects were reported in this group. Of the four subjects who received sildenafil 100 mg in the first part of this study, a severe adverse event related to blood pressure effect was reported in one patient (postural hypotension that began 35 minutes after dosing with sildenafil with symptoms lasting for 8 hours), and mild adverse events potentially related to blood pressure effects were reported in two others (dizziness, headache and fatigue at 1 hour after dosing; and dizziness, lightheadedness and nausea at 4 hours after dosing). There were no reports of syncope among these patients. For these four subjects, the placebo-subtracted mean maximum decreases from baseline in supine and standing systolic blood pressures were 14.8 mmHg and 21.5 mmHg, respectively. Two of these subjects had a standing SBP < 85mmHg. Both of these subjects were protocol violators, one due to a low baseline standing SBP, and the other due to baseline orthostatic hypotension. Study 2: Sildenafil with Doxazosin In the second study, a single oral dose of sildenafil 50 mg or matching placebo was administered in a 2-period crossover design to 20 generally healthy males with BPH. Following at least 14 consecutive days of doxazosin, sildenafil 50 mg or matching placebo was administered simultaneously with doxazosin 4 mg (17 subjects) or with doxazosin 8 mg (3 subjects). The mean subject age in this study was 63.9 years. Twenty subjects received sildenafil 50 mg, but only 19 subjects received matching placebo. One patient discontinued the study prematurely due to an adverse event of hypotension following dosing with sildenafil 50 mg. This patient had been taking minoxidil, a potent vasodilator, during the study. For the 19 subjects who received both sildenafil and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure(mm Hg) sildenafil citrate 50 mg(95% CI) Supine 9.08 (5.48, 12.68) Standing 11.62 (7.34, 15.90) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 50 mg sildenafil or matching placebo are shown in Figure 3. Blood pressure was measured after administration of sildenafil at the same times as those specified for the first doxazosin study. There were two subjects who had a standing SBP of < 85 mmHg. In these two subjects, hypotension was reported as a moderately severe adverse event, beginning at approximately 1 hour after administration of sildenafil 50 mg and resolving after approximately 7.5 hours. There was one subject with a decrease from baseline in standing systolic BP >30mmHg following sildenafil 50 mg and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil 50 mg and placebo. There were no severe adverse events potentially related to blood pressure and no episodes of syncope reported in this study. Study 3: Sildenafil with Doxazosin In the third study, a single oral dose of sildenafil 100 mg or matching placebo was administered in a 3-period crossover design to 20 generally healthy males with BPH. In dose period 1, subjects were administered open-label doxazosin and a single dose of sildenafil 50 mg simultaneously, after at least 14 consecutive days of doxazosin. If a subject did not successfully complete this first dosing period, he was discontinued from the study. Subjects who had successfully completed the previous doxazosin interaction study (using sildenafil 50 mg), including no significant hemodynamic adverse events, were allowed to skip dose period 1. Treatment with doxazosin continued for at least 7 days after dose period 1. Thereafter, sildenafil 100 mg or matching placebo was administered simultaneously with doxazosin 4 mg (14 subjects) or doxazosin 8 mg (6 subjects) in standard crossover fashion. The mean subject age in this study was 66.4 years. Twenty-five subjects were screened. Two were discontinued after study period 1: one failed to meet pre-dose screening qualifications and the other experienced symptomatic hypotension as a moderately severe adverse event 30 minutes after dosing with open-label sildenafil 50 mg. Of the twenty subjects who were ultimately assigned to treatment, a total of 13 subjects successfully completed dose period 1, and seven had successfully completed the previous doxazosin study (using sildenafil 50 mg). For the 20 subjects who received sildenafil 100 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure(mm Hg) sildenafil citrate 100 mg Supine 7.9 (4.6, 11.1) Standing 4.3 (-1.8,10.3) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 100 mg sildenafil or matching placebo are shown in Figure 4. Blood pressure was measured after administration of sildenafil at the same times as those specified for the previous doxazosin studies. There were three subjects who had a standing SBP of < 85 mmHg. All three were taking sildenafil 100 mg, and all three reported mild adverse events at the time of reductions in standing SBP, including vasodilation and lightheadedness. There were four subjects with a decrease from baseline in standing systolic BP > 30 mmHg following sildenafil 100 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil and placebo. While there were no severe adverse events potentially related to blood pressure reported in this study, one subject reported moderate vasodilatation after both sildenafil 50 mg and 100 mg. There were no episodes of syncope reported in this study. Effect of sildenafil on Blood Pressure When Co-administered with Anti-hypertensives: When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic. Effect of sildenafil on Blood Pressure When Co-administered with Alcohol: Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol (0.5 g/kg) in healthy volunteers with mean maximum blood alcohol levels of 0.08%. The maximum observed decrease in systolic blood pressure was -18.5 mmHg when sildenafil was co-administered with alcohol versus -17.4 mmHg when alcohol was administered alone. The maximum observed decrease in diastolic blood pressure was -17.2 mmHg when sildenafil was co-administered with alcohol versus -11.1 mmHg when alcohol was administered alone. There were no reports of postural dizziness or orthostatic hypotension. The maximum recommended dose of 100 mg sildenafil was not evaluated in this study [ see Drug Interactions (7.5) ]. Effects of sildenafil on Cardiac Parameters: Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers. Studies have produced relevant data on the effects of sildenafil on cardiac output. In one small, open-label, uncontrolled, pilot study, eight patients with stable ischemic heart disease underwent Swan-Ganz catheterization. A total dose of 40 mg sildenafil was administered by four intravenous infusions. The results from this pilot study are shown in Table 3; the mean resting systolic and diastolic blood pressures decreased by 7% and 10% compared to baseline in these patients. Mean resting values for right atrial pressure, pulmonary artery pressure, pulmonary artery occluded pressure and cardiac output decreased by 28%, 28%, 20% and 7% respectively. Even though this total dosage produced plasma sildenafil concentrations which were approximately 2 to 5 times higher than the mean maximum plasma concentrations following a single oral dose of 100 mg in healthy male volunteers, the hemodynamic response to exercise was preserved in these patients. Table 3. Hemodynamic Data in Patients with Stable Ischemic Heart Disease after Intravenous Administration of 40 mg of Sildenafil Means ± SD At rest After 4 minutes of exercise N Baseline (B2) n Sildenafil (D1) n Baseline n Sildenafil PAOP (mmHg) 8 8.1 ± 5.1 8 6.5 ± 4.3 8 36.0 ± 13.7 8 27.8 ± 15.3 Mean PAP (mmHg) 8 16.7 ± 4 8 12.1 ± 3.9 8 39.4 ± 12.9 8 31.7 ± 13.2 Mean RAP (mmHg) 7 5.7 ± 3.7 8 4.1 ± 3.7 - - - - Systolic SAP (mmHg) 8 150.4 ± 12.4 8 140.6 ± 16.5 8 199.5 ± 37.4 8 187.8 ± 30.0 Diastolic SAP (mmHg) 8 73.6 ± 7.8 8 65.9 ± 10 8 84.6 ± 9.7 8 79.5 ± 9.4 Cardiac output (L/min) 8 5.6 ± 0.9 8 5.2 ± 1.1 8 11.5 ± 2.4 8 10.2 ± 3.5 Heart rate (bpm) 8 67 ± 11.1 8 66.9 ± 12 8 101.9 ± 11.6 8 99.0 ± 20.4 In a double-blind study, 144 patients with erectile dysfunction and chronic stable angina limited by exercise, not receiving chronic oral nitrates, were randomized to a single dose of placebo or sildenafil 100 mg 1 hour prior to exercise testing. The primary endpoint was time to limiting angina in the evaluable cohort. The mean times (adjusted for baseline) to onset of limiting angina were 423.6 and 403.7 seconds for sildenafil (N=70) and placebo, respectively. These results demonstrated that the effect of sildenafil on the primary endpoint was statistically non-inferior to placebo. Effects of sildenafil on Vision: At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. Subjects in the study reported this finding as difficulties in discriminating blue/green. An evaluation of visual function at doses up to twice the maximum recommended dose revealed no effects of sildenafil on visual acuity, intraocular pressure, or pupillometry. Effects of sildenafil on Sperm: There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers. sildenafil-citrate-figure-1 sildenafil-citrate-figure-2 sildenafil-citrate-figure-3 sildenafil-citrate-figure-4"],"pharmacokinetics":["12.3 Pharmacokinetics Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (range 25-63%). The pharmacokinetics of sildenafil are dose-proportional over the recommended dose range. It is eliminated predominantly by hepatic metabolism (mainly CYP3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil. Both sildenafil and the metabolite have terminal half lives of about 4 hours. Mean sildenafil plasma concentrations measured after the administration of a single oral dose of 100 mg to healthy male volunteers is depicted below: Absorption and Distribution: Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When sildenafil is taken with a high fat meal, the rate of absorption is reduced, with a mean delay in T max of 60 minutes and a mean reduction in C max of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations. Based upon measurements of sildenafil in semen of healthy volunteers 90 minutes after dosing, less than 0.001% of the administered dose may appear in the semen of patients. Metabolism and Excretion: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is itself further metabolized. This metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil’s pharmacologic effects. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). Similar values for pharmacokinetic parameters were seen in normal volunteers and in the patient population, using a population pharmacokinetic approach. Pharmacokinetics in Special Populations Geriatrics: Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18-45 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.5) ] Renal Impairment: In volunteers with mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) were not altered. In volunteers with severe (CLcr <30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C max compared to age-matched volunteers with no renal impairment [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.6) ]. In addition, N-desmethyl metabolite AUC and C max values significantly increased by 200% and 79%, respectively in subjects with severe renal impairment compared to subjects with normal renal function. Hepatic Impairment: In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in increases in AUC (85%) and C max (47%) compared to age-matched volunteers with no hepatic impairment. The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.7) ]. Therefore, age >65, hepatic impairment and severe renal impairment are associated with increased plasma levels of sildenafil. A starting oral dose of 25 mg should be considered in those patients [ see Dosage and Administration (2.5) ]. Drug Interaction Studies Effects of Other Drugs on sildenafil Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. The concomitant use of erythromycin or strong CYP3A4 inhibitors (e.g., saquinavir, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil [ see Dosage and Administration (2.4) ]. In vivo studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil C max and a 182% increase in sildenafil AUC. In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil C max and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics. A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir. Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [ see Dosage and Administration (2.4) and Drug Interactions (7.4) ]. In another study in healthy male volunteers, co-administration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil C max and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics [ see Dosage and Administration (2.4) and Drug Interactions (7.4) ]. Although the interaction between other protease inhibitors and sildenafil has not been studied, their concomitant use is expected to increase sildenafil levels. In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max . Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil. Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil. In healthy male volunteers, there was no evidence of a clinically significant effect of azithromycin (500 mg daily for 3 days) on the systemic exposure of sildenafil or its major circulating metabolite. Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence. Effects of sildenafil on Other Drugs In vitro studies: Sildenafil is a weak inhibitor of the CYP isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 µM). Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes. In vivo studies: No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates. Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Sildenafil at steady state, at a dose not approved for the treatment of erectile dysfunction (80 mg t.i.d.) resulted in a 50% increase in AUC and a 42% increase in C max of bosentan (125 mg b.i.d.). sildenafil-citrate-figure-5"],"adverse_reactions":["6 ADVERSE REACTIONS The following are discussed in more detail in other sections of the labeling: Cardiovascular [ see Warnings and Precautions (5.1) ] Prolonged Erection and Priapism [ see Warnings and Precautions (5.2) ] Effects on the Eye [ see Warnings and Precautions (5.3) ] Hearing Loss [ see Warnings and Precautions (5.4) ] Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [ see Warnings and Precautions (5.5) ] Adverse Reactions with the Concomitant Use of Ritonavir [ see Warnings and Precautions (5.6) ] Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [ see Warnings and Precautions (5.7) ] Effects on Bleeding [ see Warnings and Precautions (5.8) ] Counseling Patients About Sexually Transmitted Diseases [ see Warnings and Precautions (5.9) ] The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Nivagen Pharmaceuticals, Inc. at 1-877-977-0687 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Sildenafil was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year. In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for sildenafil (2.5%) was not significantly different from placebo (2.3%). In fixed-dose studies, the incidence of some adverse reactions increased with dose. The type of adverse reactions in flexible-dose studies, which reflect the recommended dosage regimen, was similar to that for fixed- dose studies. At doses above the recommended dose range, adverse reactions were similar to those detailed in Table 1 below but generally were reported more frequently. Table 1: Adverse Reactions Reported by ≥2% of Patients Treated with sildenafil and More Frequent than Placebo in Fixed-Dose Phase II/III Studies Adverse Reaction 25 mg (n=312) 50 mg (n=511) 100 mg (n=506) Placebo (n=607) Headache 16% 21% 28% 7% Flushing 10% 19% 18% 2% Dyspepsia 3% 9% 17% 2% Abnormal vision† 1% 2% 11% 1% Nasal congestion 4% 4% 9% 2% Back pain 3% 4% 4% 2% Myalgia 2% 2% 4% 1% Nausea 2% 3% 3% 1% Dizziness 3% 4% 3% 2% Rash 1% 2% 3% 1% † Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision. When sildenafil was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials of two to twenty-six weeks duration, patients took sildenafil at least once weekly, and the following adverse reactions were reported: Table 2. Adverse Reactions Reported by ≥2% of Patients Treated with sildenafil and More Frequent than Placebo in Flexible-Dose Phase II/III Studies Adverse Reaction SILDENAFIL CITRATE PLACEBO N=734 N=725 Headache 16% 4% Flushing 10% 1% Dyspepsia 7% 2% Nasal Congestion 4% 2% Abnormal Vision † 3% 0% Back pain 2% 2% Dizziness 2% 1% Rash 2% 1% † Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision. The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to sildenafil is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Body as a Whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury. Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy. Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis. Hemic and Lymphatic: anemia and leukopenia. Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis. Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia. Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased. Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis. Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes. Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia. Analysis of the safety database from controlled clinical trials showed no apparent difference in adverse reactions in patients taking sildenafil with and without anti-hypertensive medication. This analysis was performed retrospectively, and was not powered to detect any pre-specified difference in adverse reactions. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of sildenafil . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Cardiovascular and cerebrovascular Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of sildenafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after the use of sildenafil and sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [ see Warnings and Precautions (5.1) and Patient Counseling Information (17) ]. Hemic and Lymphatic: vaso-occlusive crisis: In a small, prematurely terminated study of REVATIO (sildenafil) in patients with pulmonary arterial hypertension (PAH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported in patients who received sildenafil than in those randomized to placebo. The clinical relevance of this finding to men treated with sildenafil for ED is not known. Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia. Respiratory: epistaxis Special senses: Hearing: Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including sildenafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of sildenafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [ see Warnings and Precautions (5.4) and Patient Counseling Information (17) ]. Ocular: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal edema, retinal vascular disease or bleeding, and vitreous traction/detachment. Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking [ see Warnings and Precautions (5.3) and Patient Counseling Information (17) ]. Urogenital: prolonged erection, priapism [ see Warnings and Precautions (5.2) and Patient Counseling Information (17) ], and hematuria."],"contraindications":["4 CONTRAINDICATIONS Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets was shown to potentiate the hypotensive effect of nitrates ( 4.1 , 7.1 , 12.2 ) Known hypersensitivity to sildenafil or any component of tablet ( 4.2 ) Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 ) 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway [ see Clinical Pharmacology (12.1 , 12.2 ) ], sildenafil tablets was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [ see Dosage and Administration (2.3) , Drug Interactions (7.1) , and Clinical Pharmacology (12.2) ]. 4.2 Hypersensitivity Reactions Sildenafil tablets are contraindicated in patients with a known hypersensitivity to sildenafil, as contained in sildenafil tablets and REVATIO, or any component of the tablet. Hypersensitivity reactions have been reported, including rash and urticaria [ see Adverse Reactions (6.1) ]. 4.3 Concomitant Guanylate Cyclase (GC) Stimulators Do not use sildenafil tablets in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of GC stimulators."],"drug_interactions":["7 DRUG INTERACTIONS Sildenafil can potentiate the hypotensive effects of nitrates, alpha blockers, and anti-hypertensives ( 4.1 , 5.5 , 7.1 , 7.2 , 7.3 , 12.2 ) With concomitant use of alpha blockers, initiate sildenafil at 25 mg dose ( 2.3 ) CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin): Increase sildenafil exposure ( 2.4 , 7.4 , 12.3 ) Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48 hour period ( 2.4 , 5.6 ) Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg ( 2.4 , 7.4 ) 7.1 Nitrates Administration of sildenafil with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates [ see Dosage and Administration (2.3) , Contraindications (4.1) , Clinical Pharmacology (12.2) ]. 7.2 Alpha-blockers Use caution when co-administering alpha-blockers with sildenafil because of potential additive blood pressure-lowering effects. When sildenafil is co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil treatment and sildenafil should be initiated at the lowest dose [ see Dosage and Administration (2.3) , Warnings and Precautions (5.5) , Clinical Pharmacology (12.2) ]. 7.3 Amlodipine When sildenafil 100 mg was co-administered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic [ see Warnings and Precautions (5.5) , Clinical Pharmacology (12.2) ]. 7.4 Ritonavir and other CYP3A4 inhibitors Co-administration of ritonavir, a strong CYP3A4 inhibitor, greatly increased the systemic exposure of sildenafil (11-fold increase in AUC). It is therefore recommended not to exceed a maximum single dose of 25 mg of sildenafil in a 48 hour period [ see Dosage and Administration (2.4) , Warnings and Precautions (5.6) , Clinical Pharmacology (12.3) ]. Co-administration of erythromycin, a moderate CYP3A4 inhibitor, resulted in a 160% and 182% increases in sildenafil C max and AUC, respectively. Co-administration of saquinavir, a strong CYP3A4 inhibitor, resulted in 140% and 210% increases in sildenafil C max and AUC, respectively. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole could be expected to have greater effects than seen with saquinavir. A starting dose of 25 mg of sildenafil should be considered in patients taking erythromycin or strong CYP3A4 inhibitors (such as saquinavir, ketoconazole, itraconazole) [ see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ]. 7.5 Alcohol In a drug-drug interaction study sildenafil 50 mg given with alcohol 0.5 g/kg in which mean maximum blood alcohol levels of 0.08% was achieved, sildenafil did not potentiate the hypotensive effect of alcohol in healthy volunteers [ see Clinical Pharmacology (12.2) ]."],"mechanism_of_action":["12.1 Mechanism of Action The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation. Binding Characteristics Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). Sildenafil is approximately 4,000-fold more selective for PDE5 compared to PDE3. PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina which is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision [ see Clinical Pharmacology (12.2) ]. In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in some of these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of NO observed in vitro , an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo."],"recent_major_changes":["Warnings and Precautions, Effects on the Eye (5.3) 08/2017"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation. Binding Characteristics Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). Sildenafil is approximately 4,000-fold more selective for PDE5 compared to PDE3. PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina which is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision [ see Clinical Pharmacology (12.2) ]. In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in some of these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of NO observed in vitro , an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo. 12.2 Pharmacodynamics Effects of sildenafil on Erectile Response: In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (RigiScan ® ), after sildenafil administration compared with placebo. Most studies assessed the efficacy of sildenafil approximately 60 minutes post dose. The erectile response, as assessed by RigiScan ® , generally increased with increasing sildenafil dose and plasma concentration. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours. Effects of sildenafil on Blood Pressure: Single oral doses of sildenafil (100 mg) administered to healthy volunteers produced decreases in sitting blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8.3/5.3 mmHg). The decrease in sitting blood pressure was most notable approximately 1-2 hours after dosing, and was not different than placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [ see Contraindications (4.1) ]. Effects of sildenafil on Blood Pressure When Nitroglycerin is Subsequently Administered: Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL). In the following patients: age >65 years, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of erythromycin or strong CYP3A4 inhibitors, plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [ see Contraindications (4.1) ]. Effects of sildenafil on Blood Pressure When Co-administered with Alpha-Blockers: Three double-blind, placebo-controlled, randomized, two-way crossover studies were conducted to assess the interaction of sildenafil with doxazosin, an alpha-adrenergic blocking agent. Study 1: Sildenafil with Doxazosin In the first study, a single oral dose of sildenafil 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH). Following at least 14 consecutive daily doses of doxazosin, sildenafil 100 mg or matching placebo was administered simultaneously with doxazosin. Following a review of the data from these first 4 subjects (details provided below), the sildenafil dose was reduced to 25 mg. Thereafter, 17 subjects were treated with sildenafil 25 mg or matching placebo in combination with doxazosin 4 mg (15 subjects) or doxazosin 8 mg (2 subjects). The mean subject age was 66.5 years. For the 17 subjects who received sildenafil 25 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg) sildenafil citrate 25 mg Supine 7.4 (-0.9, 15.7) Standing 6.0 (-0.8, 12.8) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 25 mg sildenafil or matching placebo are shown in Figure 2. Blood pressure was measured immediately pre-dose and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours after sildenafil or matching placebo. Outliers were defined as subjects with a standing systolic blood pressure of <85 mmHg or a decrease from baseline in standing systolic blood pressure of >30 mmHg at one or more timepoints. There were no subjects treated with sildenafil 25 mg who had a standing SBP < 85mmHg. There were three subjects with a decrease from baseline in standing systolic BP >30mmHg following sildenafil 25 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and two subjects with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil and placebo. No severe adverse events potentially related to blood pressure effects were reported in this group. Of the four subjects who received sildenafil 100 mg in the first part of this study, a severe adverse event related to blood pressure effect was reported in one patient (postural hypotension that began 35 minutes after dosing with sildenafil with symptoms lasting for 8 hours), and mild adverse events potentially related to blood pressure effects were reported in two others (dizziness, headache and fatigue at 1 hour after dosing; and dizziness, lightheadedness and nausea at 4 hours after dosing). There were no reports of syncope among these patients. For these four subjects, the placebo-subtracted mean maximum decreases from baseline in supine and standing systolic blood pressures were 14.8 mmHg and 21.5 mmHg, respectively. Two of these subjects had a standing SBP < 85mmHg. Both of these subjects were protocol violators, one due to a low baseline standing SBP, and the other due to baseline orthostatic hypotension. Study 2: Sildenafil with Doxazosin In the second study, a single oral dose of sildenafil 50 mg or matching placebo was administered in a 2-period crossover design to 20 generally healthy males with BPH. Following at least 14 consecutive days of doxazosin, sildenafil 50 mg or matching placebo was administered simultaneously with doxazosin 4 mg (17 subjects) or with doxazosin 8 mg (3 subjects). The mean subject age in this study was 63.9 years. Twenty subjects received sildenafil 50 mg, but only 19 subjects received matching placebo. One patient discontinued the study prematurely due to an adverse event of hypotension following dosing with sildenafil 50 mg. This patient had been taking minoxidil, a potent vasodilator, during the study. For the 19 subjects who received both sildenafil and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure(mm Hg) sildenafil citrate 50 mg(95% CI) Supine 9.08 (5.48, 12.68) Standing 11.62 (7.34, 15.90) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 50 mg sildenafil or matching placebo are shown in Figure 3. Blood pressure was measured after administration of sildenafil at the same times as those specified for the first doxazosin study. There were two subjects who had a standing SBP of < 85 mmHg. In these two subjects, hypotension was reported as a moderately severe adverse event, beginning at approximately 1 hour after administration of sildenafil 50 mg and resolving after approximately 7.5 hours. There was one subject with a decrease from baseline in standing systolic BP >30mmHg following sildenafil 50 mg and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil 50 mg and placebo. There were no severe adverse events potentially related to blood pressure and no episodes of syncope reported in this study. Study 3: Sildenafil with Doxazosin In the third study, a single oral dose of sildenafil 100 mg or matching placebo was administered in a 3-period crossover design to 20 generally healthy males with BPH. In dose period 1, subjects were administered open-label doxazosin and a single dose of sildenafil 50 mg simultaneously, after at least 14 consecutive days of doxazosin. If a subject did not successfully complete this first dosing period, he was discontinued from the study. Subjects who had successfully completed the previous doxazosin interaction study (using sildenafil 50 mg), including no significant hemodynamic adverse events, were allowed to skip dose period 1. Treatment with doxazosin continued for at least 7 days after dose period 1. Thereafter, sildenafil 100 mg or matching placebo was administered simultaneously with doxazosin 4 mg (14 subjects) or doxazosin 8 mg (6 subjects) in standard crossover fashion. The mean subject age in this study was 66.4 years. Twenty-five subjects were screened. Two were discontinued after study period 1: one failed to meet pre-dose screening qualifications and the other experienced symptomatic hypotension as a moderately severe adverse event 30 minutes after dosing with open-label sildenafil 50 mg. Of the twenty subjects who were ultimately assigned to treatment, a total of 13 subjects successfully completed dose period 1, and seven had successfully completed the previous doxazosin study (using sildenafil 50 mg). For the 20 subjects who received sildenafil 100 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure(mm Hg) sildenafil citrate 100 mg Supine 7.9 (4.6, 11.1) Standing 4.3 (-1.8,10.3) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 100 mg sildenafil or matching placebo are shown in Figure 4. Blood pressure was measured after administration of sildenafil at the same times as those specified for the previous doxazosin studies. There were three subjects who had a standing SBP of < 85 mmHg. All three were taking sildenafil 100 mg, and all three reported mild adverse events at the time of reductions in standing SBP, including vasodilation and lightheadedness. There were four subjects with a decrease from baseline in standing systolic BP > 30 mmHg following sildenafil 100 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both sildenafil and placebo. While there were no severe adverse events potentially related to blood pressure reported in this study, one subject reported moderate vasodilatation after both sildenafil 50 mg and 100 mg. There were no episodes of syncope reported in this study. Effect of sildenafil on Blood Pressure When Co-administered with Anti-hypertensives: When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic. Effect of sildenafil on Blood Pressure When Co-administered with Alcohol: Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol (0.5 g/kg) in healthy volunteers with mean maximum blood alcohol levels of 0.08%. The maximum observed decrease in systolic blood pressure was -18.5 mmHg when sildenafil was co-administered with alcohol versus -17.4 mmHg when alcohol was administered alone. The maximum observed decrease in diastolic blood pressure was -17.2 mmHg when sildenafil was co-administered with alcohol versus -11.1 mmHg when alcohol was administered alone. There were no reports of postural dizziness or orthostatic hypotension. The maximum recommended dose of 100 mg sildenafil was not evaluated in this study [ see Drug Interactions (7.5) ]. Effects of sildenafil on Cardiac Parameters: Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers. Studies have produced relevant data on the effects of sildenafil on cardiac output. In one small, open-label, uncontrolled, pilot study, eight patients with stable ischemic heart disease underwent Swan-Ganz catheterization. A total dose of 40 mg sildenafil was administered by four intravenous infusions. The results from this pilot study are shown in Table 3; the mean resting systolic and diastolic blood pressures decreased by 7% and 10% compared to baseline in these patients. Mean resting values for right atrial pressure, pulmonary artery pressure, pulmonary artery occluded pressure and cardiac output decreased by 28%, 28%, 20% and 7% respectively. Even though this total dosage produced plasma sildenafil concentrations which were approximately 2 to 5 times higher than the mean maximum plasma concentrations following a single oral dose of 100 mg in healthy male volunteers, the hemodynamic response to exercise was preserved in these patients. Table 3. Hemodynamic Data in Patients with Stable Ischemic Heart Disease after Intravenous Administration of 40 mg of Sildenafil Means ± SD At rest After 4 minutes of exercise N Baseline (B2) n Sildenafil (D1) n Baseline n Sildenafil PAOP (mmHg) 8 8.1 ± 5.1 8 6.5 ± 4.3 8 36.0 ± 13.7 8 27.8 ± 15.3 Mean PAP (mmHg) 8 16.7 ± 4 8 12.1 ± 3.9 8 39.4 ± 12.9 8 31.7 ± 13.2 Mean RAP (mmHg) 7 5.7 ± 3.7 8 4.1 ± 3.7 - - - - Systolic SAP (mmHg) 8 150.4 ± 12.4 8 140.6 ± 16.5 8 199.5 ± 37.4 8 187.8 ± 30.0 Diastolic SAP (mmHg) 8 73.6 ± 7.8 8 65.9 ± 10 8 84.6 ± 9.7 8 79.5 ± 9.4 Cardiac output (L/min) 8 5.6 ± 0.9 8 5.2 ± 1.1 8 11.5 ± 2.4 8 10.2 ± 3.5 Heart rate (bpm) 8 67 ± 11.1 8 66.9 ± 12 8 101.9 ± 11.6 8 99.0 ± 20.4 In a double-blind study, 144 patients with erectile dysfunction and chronic stable angina limited by exercise, not receiving chronic oral nitrates, were randomized to a single dose of placebo or sildenafil 100 mg 1 hour prior to exercise testing. The primary endpoint was time to limiting angina in the evaluable cohort. The mean times (adjusted for baseline) to onset of limiting angina were 423.6 and 403.7 seconds for sildenafil (N=70) and placebo, respectively. These results demonstrated that the effect of sildenafil on the primary endpoint was statistically non-inferior to placebo. Effects of sildenafil on Vision: At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. Subjects in the study reported this finding as difficulties in discriminating blue/green. An evaluation of visual function at doses up to twice the maximum recommended dose revealed no effects of sildenafil on visual acuity, intraocular pressure, or pupillometry. Effects of sildenafil on Sperm: There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers. sildenafil-citrate-figure-1 sildenafil-citrate-figure-2 sildenafil-citrate-figure-3 sildenafil-citrate-figure-4 12.3 Pharmacokinetics Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (range 25-63%). The pharmacokinetics of sildenafil are dose-proportional over the recommended dose range. It is eliminated predominantly by hepatic metabolism (mainly CYP3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil. Both sildenafil and the metabolite have terminal half lives of about 4 hours. Mean sildenafil plasma concentrations measured after the administration of a single oral dose of 100 mg to healthy male volunteers is depicted below: Absorption and Distribution: Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When sildenafil is taken with a high fat meal, the rate of absorption is reduced, with a mean delay in T max of 60 minutes and a mean reduction in C max of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations. Based upon measurements of sildenafil in semen of healthy volunteers 90 minutes after dosing, less than 0.001% of the administered dose may appear in the semen of patients. Metabolism and Excretion: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is itself further metabolized. This metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil’s pharmacologic effects. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). Similar values for pharmacokinetic parameters were seen in normal volunteers and in the patient population, using a population pharmacokinetic approach. Pharmacokinetics in Special Populations Geriatrics: Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18-45 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.5) ] Renal Impairment: In volunteers with mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) were not altered. In volunteers with severe (CLcr <30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C max compared to age-matched volunteers with no renal impairment [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.6) ]. In addition, N-desmethyl metabolite AUC and C max values significantly increased by 200% and 79%, respectively in subjects with severe renal impairment compared to subjects with normal renal function. Hepatic Impairment: In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in increases in AUC (85%) and C max (47%) compared to age-matched volunteers with no hepatic impairment. The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied [ see Dosage and Administration (2.5) , and Use in Specific Populations (8.7) ]. Therefore, age >65, hepatic impairment and severe renal impairment are associated with increased plasma levels of sildenafil. A starting oral dose of 25 mg should be considered in those patients [ see Dosage and Administration (2.5) ]. Drug Interaction Studies Effects of Other Drugs on sildenafil Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. The concomitant use of erythromycin or strong CYP3A4 inhibitors (e.g., saquinavir, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil [ see Dosage and Administration (2.4) ]. In vivo studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil C max and a 182% increase in sildenafil AUC. In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil C max and a 210% increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics. A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir. Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [ see Dosage and Administration (2.4) and Drug Interactions (7.4) ]. In another study in healthy male volunteers, co-administration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil C max and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics [ see Dosage and Administration (2.4) and Drug Interactions (7.4) ]. Although the interaction between other protease inhibitors and sildenafil has not been studied, their concomitant use is expected to increase sildenafil levels. In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max . Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil. Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil. In healthy male volunteers, there was no evidence of a clinically significant effect of azithromycin (500 mg daily for 3 days) on the systemic exposure of sildenafil or its major circulating metabolite. Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence. Effects of sildenafil on Other Drugs In vitro studies: Sildenafil is a weak inhibitor of the CYP isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 µM). Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes. In vivo studies: No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates. Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Sildenafil at steady state, at a dose not approved for the treatment of erectile dysfunction (80 mg t.i.d.) resulted in a 50% increase in AUC and a 42% increase in C max of bosentan (125 mg b.i.d.). sildenafil-citrate-figure-5"],"indications_and_usage":["1 INDICATIONS AND USAGE Sildenafil tablets are indicated for the treatment of erectile dysfunction. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Patients should not use sildenafil if sexual activity is inadvisable due to cardiovascular status ( 5.1 ) Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil with caution in patients predisposed to priapism ( 5.2 ) Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Sildenafil tablets should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a \"crowded\" optic disc may also be at an increased risk of NAION. ( 5.3 ) Patients should stop sildenafil tablets and seek prompt medical attention in the event of sudden decrease or loss of hearing ( 5.4 ) Caution is advised when sildenafil is co-administered with alpha-blockers or anti-hypertensives. Concomitant use may lead to hypotension ( 5.5 ) Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors, such as ritonavir, sildenafil exposure is increased. Decrease in sildenafil dosage is recommended ( 2.4 , 5.6 ) 5.1 Cardiovascular There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including sildenafil, should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment. Sildenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [ see Clinical Pharmacology (12.2) ]. While this normally would be expected to be of little consequence in most patients, prior to prescribing sildenafil, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil - those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure. There are no controlled clinical data on the safety or efficacy of sildenafil in the following groups; if prescribed, this should be done with caution. Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); Patients with cardiac failure or coronary artery disease causing unstable angina. 5.2 Prolonged Erection and Priapism Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil tablets. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). However, there are no controlled clinical data on the safety or efficacy of sildenafil in patients with sickle cell or related anemias. 5.3 Effects on the Eye Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil , and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged ≥ 50. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [ see Adverse Reactions (6.2) ]. Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, PDE5 inhibitors, including sildenafil , should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including sildenafil, for this uncommon condition. There are no controlled clinical data on the safety or efficacy of sildenafil in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. 5.4 Hearing Loss Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil , and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including sildenafil . It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [ see Adverse Reactions (6.1 , 6.2) ]. 5.5 Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may occur. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [ see Drug Interactions (7.2) and Clinical Pharmacology (12.2) ] leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting). Consideration should be given to the following: Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [ see Dosage and Administration (2.3) ]. In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. Anti-hypertensives Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-­hypertensive medications. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and sildenafil, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [ see Drug Interactions (7.3) and Clinical Pharmacology (12.2) ]. 5.6 Adverse Reactions with the Concomitant Use of Ritonavir The concomitant administration of the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil (11-fold increase in AUC). If sildenafil is prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of sildenafil are limited. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To decrease the chance of adverse reactions in patients taking ritonavir, a decrease in sildenafil dosage is recommended [ see Dosage and Administration (2.4) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ]. 5.7 Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied. Such combinations may further lower blood pressure. Therefore, the use of such combinations is not recommended. 5.8 Effects on Bleeding There have been postmarketing reports of bleeding events in patients who have taken sildenafil . A causal relationship between sildenafil and these events has not been established. In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. However, in vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). In addition, the combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. The safety of sildenafil is unknown in patients with bleeding disorders and patients with active peptic ulceration. 5.9 Counseling Patients About Sexually Transmitted Diseases The use of sildenafil offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Sildenafil was not carcinogenic when administered to rats for 24 months at a dose resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its major metabolite of 20- and 38- times, for male and female rats, respectively, the exposures observed in human males given the Maximum Recommended Human Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 10 mg/kg/day, approximately 0.4 times the MRHD on a mg/m 2 basis in a 50 kg subject. Mutagenesis Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and in vitro human lymphocytes and in vivo mouse micronucleus assays to detect clastogenicity. Impairment of Fertility There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC."],"pharmacodynamics_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"588\"><col width=\"58.1632653061224%\"/><col width=\"41.8367346938776%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure (mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 25 mg  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 7.4 (-0.9, 15.7)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 6.0 (-0.8, 12.8)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"607\"><col width=\"54.3657331136738%\"/><col width=\"45.6342668863262%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure(mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 50 mg(95% CI)  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 9.08 (5.48, 12.68)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 11.62 (7.34, 15.90)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"606\"><col width=\"60.3960396039604%\"/><col width=\"39.6039603960396%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure(mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 100 mg  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 7.9 (4.6, 11.1)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 4.3 (-1.8,10.3)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"659\"><col width=\"17.3271330367974%\"/><col width=\"6.55074807925596%\"/><col width=\"16.4880711686211%\"/><col width=\"3.9122523251112%\"/><col width=\"16.0735948241003%\"/><col width=\"4.85240598463405%\"/><col width=\"14.9818034775576%\"/><col width=\"3.76061463809139%\"/><col width=\"16.053376465831%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Means &#xB1; SD  </td><td colspan=\"4\" align=\"center\" styleCode=\"Rrule\" valign=\"top\">At rest  </td><td colspan=\"4\" styleCode=\"Rrule\" valign=\"top\">After 4 minutes of exercise  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">N  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Baseline (B2)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Sildenafil (D1)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Baseline  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Sildenafil  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">PAOP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8.1 &#xB1; 5.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">6.5 &#xB1; 4.3  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">36.0 &#xB1; 13.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">27.8 &#xB1; 15.3  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Mean PAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">16.7 &#xB1; 4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">12.1 &#xB1; 3.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">39.4 &#xB1; 12.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">31.7 &#xB1; 13.2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Mean RAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.7 &#xB1; 3.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.1 &#xB1; 3.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Systolic SAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">150.4 &#xB1; 12.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">140.6 &#xB1; 16.5  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">199.5 &#xB1; 37.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">187.8 &#xB1; 30.0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Diastolic SAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">73.6 &#xB1; 7.8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">65.9 &#xB1; 10  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">84.6 &#xB1; 9.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">79.5 &#xB1; 9.4  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Cardiac output (L/min)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.6 &#xB1; 0.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.2 &#xB1; 1.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">11.5 &#xB1; 2.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.2 &#xB1; 3.5  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">Heart rate (bpm)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">67 &#xB1; 11.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">66.9 &#xB1; 12  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">101.9 &#xB1; 11.6  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">99.0 &#xB1; 20.4  </td></tr></tbody></table>"],"adverse_reactions_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"668\"><col width=\"22.6302135302335%\"/><col width=\"18.9582917581321%\"/><col width=\"18.9582917581321%\"/><col width=\"19.0979844342447%\"/><col width=\"20.3552185192576%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Adverse Reaction  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">25 mg   (n=312)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">50 mg   (n=511)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">100 mg   (n=506)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Placebo   (n=607)  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Headache  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">16%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">21%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">28%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">7%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Flushing  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">10%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">19%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">18%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Dyspepsia  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">9%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">17%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Abnormal vision&#x2020;  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">11%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Nasal congestion  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">9%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Back pain  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Myalgia  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Nausea  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Dizziness  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">4%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Rash  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">2%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3%  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">1%  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"547\"><col width=\"29.8245614035088%\"/><col width=\"44.9561403508772%\"/><col width=\"25.219298245614%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Adverse Reaction  </td><td styleCode=\"Rrule\" valign=\"top\"> SILDENAFIL CITRATE  </td><td styleCode=\"Rrule\" valign=\"top\">PLACEBO  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td styleCode=\"Rrule\" valign=\"top\">N=734  </td><td styleCode=\"Rrule\" valign=\"top\">N=725  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Headache  </td><td styleCode=\"Rrule\" valign=\"top\">16%  </td><td styleCode=\"Rrule\" valign=\"top\">4%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Flushing  </td><td styleCode=\"Rrule\" valign=\"top\">10%  </td><td styleCode=\"Rrule\" valign=\"top\">1%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Dyspepsia  </td><td styleCode=\"Rrule\" valign=\"top\">7%  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Nasal Congestion  </td><td styleCode=\"Rrule\" valign=\"top\">4%  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Abnormal Vision &#x2020;  </td><td styleCode=\"Rrule\" valign=\"top\">3%  </td><td styleCode=\"Rrule\" valign=\"top\">0%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Back pain  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Dizziness  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td><td styleCode=\"Rrule\" valign=\"top\">1%  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Rash  </td><td styleCode=\"Rrule\" valign=\"top\">2%  </td><td styleCode=\"Rrule\" valign=\"top\">1%  </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) Nitrates Physicians should discuss with patients the contraindication of sildenafil with regular and/or intermittent use of nitric oxide donors, such as organic nitrates or organic nitrites in any form [ see Contraindications (4.1) ]. Guanylate Cyclase (GC) Stimulators Physicians should discuss with patients the contraindication of sildenafil with use of guanylate cyclase stimulators such as riociguat [ see Contraindications (4.3) ]. Concomitant Use with Drugs Which Lower Blood Pressure Physicians should advise patients of the potential for sildenafil to augment the blood pressure lowering effect of alpha-blockers and anti-hypertensive medications. Concomitant administration of sildenafil and an alpha - blocker may lead to symptomatic hypotension in some patients. Therefore, when sildenafil is co-administered with alpha-blockers, patients should be stable on alpha-blocker therapy prior to initiating sildenafil treatment and sildenafil should be initiated at the lowest dose [ see Warnings and Precautions (5.5) ]. Cardiovascular Considerations Physicians should discuss with patients the potential cardiac risk of sexual activity in patients with preexisting cardiovascular risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, nausea) upon initiation of sexual activity should be advised to refrain from further activity and should discuss the episode with their physician [ see Warnings and Precautions (5.1) ]. Sudden Loss of Vision Physicians should advise patients to stop use of all PDE5 inhibitors, including sildenafil, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including possible permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. Physicians should discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye. Physicians should also discuss with patients the increased risk of NAION among the general population in patients with a “crowded” optic disc, although evidence is insufficient to support screening of prospective users of PDE5 inhibitor, including sildenafil, for this uncommon condition [ see Warnings and Precautions (5.3) and Adverse Reactions (6.2) ]. Sudden Hearing Loss Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including sildenafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [ see Warnings and Precautions (5.4) and Adverse Reactions (6.2) ]. Priapism Physicians should warn patients that prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of sildenafil. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result [ see Warnings and Precautions (5.2) ]. Avoid Use with other PDE5 Inhibitors Physicians should inform patients not to take sildenafil tablets with other PDE5 inhibitors including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil. Sildenafil is also marketed as REVATIO for the treatment of PAH. The safety and efficacy of sildenafil tablets with other PDE5 inhibitors, including REVATIO, have not been studied [ see Warnings and Precautions (5.7) ]. Sexually Transmitted Disease The use of sildenafil offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered [ see Warnings and Precautions (5.9) ]. Manufactured by: Umedica Laboratories Pvt. Ltd. Plot No. 221 and 221/1, GIDC, II nd Phase, Vapi, Gujarat 396195, India (IND) Manufactured for: Nivagen Pharmaceuticals, Inc. Sacramento, CA 95827, USA Toll free number: 1-877-977-0687 Revised: June 2023, V-03 Patient Information Sildenafil (sil den' a fil ) Tablets USP What is the most important information I should know about sildenafil ? Sildenafil tablets can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines . Do not take sildenafil tablets if you take any other medicines called “nitrates.” Nitrates are used to treat chest pain (angina). A sudden drop in blood pressure can cause you to feel dizzy, faint, or have a heart attack or stroke. Do not take sildenafil tablets if you take medicines called guanylate cyclase stimulators which include: • Riociguat (Adempas ® ) a medicine that treats pulmonary arterial hypertension and chronic­-thromboembolic pulmonary hypertension. Tell all your healthcare providers that you take sildenafil tablets. If you need emergency medical care for a heart problem, it will be important for your healthcare provider to know when you last took sildenafil tablets. Stop sexual activity and get medical help right away if you get symptoms such as chest pain, dizziness, or nausea during sex. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease. Ask your doctor if your heart is healthy enough to handle the extra strain of having sex. Sildenafil tablets does not protect you or your partner from getting sexually transmitted diseases, including HIV-the virus that causes AIDS. What are sildenafil tablets? Sildenafil tablets are a prescription medicine used to treat erectile dysfunction (ED). You will not get an erection just by taking this medicine. Sildenafil tablets helps a man with erectile dysfunction get and keep an erection only when he is sexually excited (stimulated). Sildenafil tablets are not for use in women or children. It is not known if sildenafil tablets are safe and effective in women or children under 18 years of age. Who should not take sildenafil tablets? Do not take sildenafil tablets if you: take medicines called nitrates (such as nitroglycerin) use street drugs called “poppers” such as amyl nitrate or amyl nitrite, and butyl nitrate take any medicines called guanylate cyclase stimulators such as riociguat (Adempas) are allergic to sildenafil, as contained in sildenafil tablets and REVATIO, or any of the ingredients in sildenafil tablets. See the end of this leaflet for a complete list of ingredients in sildenafil tablets. What should I tell my healthcare provider before taking sildenafil tablets? Before you take sildenafil tablets, tell your healthcare provider if you: have or have had heart problems such as a heart attack, irregular heartbeat, angina, chest pain, narrowing of the aortic valve or heart failure have had heart surgery within the last 6 months have pulmonary hypertension have had a stroke have low blood pressure, or high blood pressure that is not controlled have a deformed penis shape have had an erection that lasted for more than 4 hours have problems with your blood cells such as sickle cell anemia, multiple myeloma, or leukemia have retinitis pigmentosa, a rare genetic (runs in families) eye disease have ever had severe vision loss, including an eye problem called non-arteritic anterior ischemic optic neuropathy (NAION) have bleeding problems have or have had stomach ulcers have liver problems have kidney problems or are having kidney dialysis have any other medical conditions Tell your healthcare provider about all the medicines you take*, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sildenafil tablets may affect the way other medicines work, and other medicines may affect the way sildenafil tablets works causing side effects. Especially tell your healthcare provider if you take any of the following: medicines called nitrates (see “What is the most important information I should know about sildenafil tablets?” ) medicines called guanylate cyclase stimulators, such as riociguat (Adempas) medicines called alpha blockers such as Hytrin (terazosin HCl), Flomax (tamsulosin HCl), Cardura (doxazosin mesylate), Minipress (prazosin HCl), Uroxatral (alfuzosin HCl), Jalyn (dutasteride and tamsulosin HCl), or Rapaflo (silodosin). Alpha-blockers are sometimes prescribed for prostate problems or high blood pressure. In some patients, the use of sildenafil tablets with alpha-blockers can lead to a drop in blood pressure or to fainting. medicines called HIV protease inhibitors, such as ritonavir (Norvir), indinavir sulfate (Crixivan), saquinavir (Fortovase or Invirase) or atazanavir sulfate (Reyataz) some types of oral antifungal medicines, such as ketoconazole (Nizoral), and itraconazole (Sporanox) some types of antibiotics, such as clarithromycin (Biaxin), telithromycin (Ketek), or erythromycin other medicines that treat high blood pressure other medicines or treatments for ED Sildenafil tablets contains sildenafil, which is the same medicine found in another drug called REVATIO. REVATIO is used to treat a rare disease called pulmonary arterial hypertension (PAH). Sildenafil tablets should not be used with REVATIO or with other PAH treatments containing sildenafil or any other PDE5 inhibitors (such as Adcirca [tadalafil]). Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. How should I take sildenafil tablets? Take sildenafil tablets exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you how much sildenafil tablets to take and when to take it. Your healthcare provider may change your dose if needed. Take sildenafil tablets about 1 hour before sexual activity. You may take sildenafil tablets between 30 minutes to 4 hours before sexual activity if needed. Sildenafil tablets can be taken with or without food. If you take sildenafil tablets after a high fat meal (such as a cheeseburger and french fries), sildenafil tablets may take a little longer to start working Do not take sildenafil tablets more than 1 time a day. If you accidentally take too much sildenafil, call your doctor or go to the nearest hospital emergency room right away. What are the possible side effects of sildenafil tablets? Sildenafil tablets can cause serious side effects. Rarely reported side effects include: an erection that will not go away (priapism). If you have an erection that lasts more than 4 hours, get medical help right away. If it is not treated right away, priapism can permanently damage your penis. sudden vision loss in one or both eyes. Sudden vision loss in one or both eyes can be a sign of a serious eye problem called non-arteritic anterior ischemic optic neuropathy (NAION). It is uncertain whether PDE5 inhibitors directly cause the vision loss. Stop taking sildenafil tablets and call your healthcare provider right away if you have sudden vision loss in one or both eyes. sudden hearing decrease or hearing loss . Some people may also have ringing in their ears (tinnitus) or dizziness. If you have these symptoms, stop taking sildenafil tablets and contact a doctor right away. The most common side effects of sildenafil tablets are: headache flushing upset stomach abnormal vision, such as changes in color vision (such as having a blue color tinge) and blurred vision stuffy or runny nose back pain muscle pain nausea dizziness rash In addition, heart attack, stroke, irregular heartbeats and death have happened rarely in men taking sildenafil tablets. Most, but not all, of these men had heart problems before taking sildenafil tablets. It is not known if sildenafil tablets caused these problems. Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of sildenafil tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1­-800-FDA-1088. How should I store sildenafil tablets? Store sildenafil tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep sildenafil tablets and all medicines out of the reach of children. General information about the safe and effective use of sildenafil tablets. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use sildenafil tablets for a condition for which it was not prescribed. Do not give sildenafil tablets to other people, even if they have the same symptoms that you have. It may harm them. This Patient Information leaflet summarizes the most important information about sildenafil tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about sildenafil tablets that is written for health professionals. For more information, call Nivagen Pharmaceuticals, Inc. at 1-877-977-0687. What are the ingredients in sildenafil tablets? Active ingredient: sildenafil citrate, USP Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dicalcium phosphate anhydrous, FD&C Blue # 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin. This Patient Information has been approved by the U.S. Food and Drug Administration. Manufactured by: Umedica Laboratories Pvt. Ltd. Plot No. 221 and 221/1, GIDC, II nd Phase, Vapi, Gujarat 396195, India (IND) Manufactured for: Nivagen Pharmaceuticals, Inc. Sacramento, CA 95827, USA Toll free number: 1-877-977-0687 Revised: June 2023, V-03 *The other brands listed are trademarks of their respective owners and are not trademarks of Umedica Laboratories Pvt. Ltd. The makers of these brands are not affiliated with and do not endorse Umedica Laboratories Pvt. Ltd. or its products."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity ( 2.1 ) Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg ( 2.1 ) Maximum recommended dosing frequency is once per day ( 2.1 ) 2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity. The maximum recommended dosing frequency is once per day. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. 2.2 Use with Food Sildenafil tablets may be taken with or without food. 2.3 Dosage Adjustments in Specific Situations Sildenafil tablets was shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated [ see Contraindications (4.1) , Drug Interactions (7.1) , and Clinical Pharmacology (12.2) ]. When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg [ see Warnings and Precautions (5.5) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. 2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [ see Warnings and Precautions (5.6) , Drug Interactions (7.4) , and Clinical Pharmacology (12.3) ]. CYP3A4 Inhibitors Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [ see Drug Interactions (7.4) and Clinical Pharmacology (12.3) ]. 2.5 Dosage Adjustments in Special Populations Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of sildenafil tablets in these patients resulted in higher plasma levels of sildenafil [ see Use in Specific Populations (8.5 , 8.6, 8.7) and Clinical Pharmacology (12.3) ]."],"spl_product_data_elements":["SILDENAFIL CITRATE SILDENAFIL CITRATE CELLULOSE, MICROCRYSTALLINE SILICON DIOXIDE CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS CROSCARMELLOSE SODIUM MAGNESIUM STEARATE HYPROMELLOSES TITANIUM DIOXIDE LACTOSE MONOHYDRATE TRIACETIN FD&C BLUE NO. 2 SILDENAFIL CITRATE SILDENAFIL 25;SL"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Sildenafil tablets, USP are supplied as pale blue to blue, caplet shaped film-coated tablets containing sildenafil citrate USP equivalent to 50 mg, or 100 mg of sildenafil. Tablets are debossed with 1A1 and 1A2 on one side and plain on the other to indicate the dosage strengths viz. 100 mg and 50 mg respectively. Sildenafil tablets 25 mg USP is supplied as Pale blue to blue, round film-coated tablets, debossed with “25” on one side and “SL” on other side. Tablets: 25 mg, 50 mg and 100 mg"],"spl_patient_package_insert":[""],"clinical_pharmacology_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"588\"><col width=\"58.1632653061224%\"/><col width=\"41.8367346938776%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure (mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 25 mg  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 7.4 (-0.9, 15.7)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 6.0 (-0.8, 12.8)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"607\"><col width=\"54.3657331136738%\"/><col width=\"45.6342668863262%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure(mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 50 mg(95% CI)  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 9.08 (5.48, 12.68)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 11.62 (7.34, 15.90)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"606\"><col width=\"60.3960396039604%\"/><col width=\"39.6039603960396%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Placebo-subtracted mean maximum decrease   in systolic blood pressure(mm Hg)  </td><td styleCode=\"Rrule\" valign=\"top\"> sildenafil citrate 100 mg  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"> Supine  </td><td styleCode=\"Rrule\" valign=\"top\"> 7.9 (4.6, 11.1)  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\"> Standing  </td><td styleCode=\"Rrule\" valign=\"top\"> 4.3 (-1.8,10.3)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"659\"><col width=\"17.3271330367974%\"/><col width=\"6.55074807925596%\"/><col width=\"16.4880711686211%\"/><col width=\"3.9122523251112%\"/><col width=\"16.0735948241003%\"/><col width=\"4.85240598463405%\"/><col width=\"14.9818034775576%\"/><col width=\"3.76061463809139%\"/><col width=\"16.053376465831%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Means &#xB1; SD  </td><td colspan=\"4\" align=\"center\" styleCode=\"Rrule\" valign=\"top\">At rest  </td><td colspan=\"4\" styleCode=\"Rrule\" valign=\"top\">After 4 minutes of exercise  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">N  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Baseline (B2)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Sildenafil (D1)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Baseline  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">n  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">Sildenafil  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">PAOP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8.1 &#xB1; 5.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">6.5 &#xB1; 4.3  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">36.0 &#xB1; 13.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">27.8 &#xB1; 15.3  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Mean PAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">16.7 &#xB1; 4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">12.1 &#xB1; 3.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">39.4 &#xB1; 12.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">31.7 &#xB1; 13.2  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Mean RAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.7 &#xB1; 3.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.1 &#xB1; 3.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">-  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Systolic SAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">150.4 &#xB1; 12.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">140.6 &#xB1; 16.5  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">199.5 &#xB1; 37.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">187.8 &#xB1; 30.0  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Diastolic SAP (mmHg)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">73.6 &#xB1; 7.8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">65.9 &#xB1; 10  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">84.6 &#xB1; 9.7  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">79.5 &#xB1; 9.4  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Cardiac output (L/min)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.6 &#xB1; 0.9  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">5.2 &#xB1; 1.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">11.5 &#xB1; 2.4  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.2 &#xB1; 3.5  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">Heart rate (bpm)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">67 &#xB1; 11.1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">66.9 &#xB1; 12  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">101.9 &#xB1; 11.6  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">8  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">99.0 &#xB1; 20.4  </td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Geriatric use: Consider a starting dose of 25 mg ( 2.5 , 8.5 ) Severe renal impairment: Consider a starting dose of 25 mg ( 2.5 , 8.6 ) Hepatic impairment: Consider a starting dose of 25 mg ( 2.5 , 8.7 ) 8.1 Pregnancy Risk Summary Sildenafil is not indicated for use in females. There are no data with the use of sildenafil in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m 2 basis ( see Data ). Data Animal Data No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m 2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m 2 basis in a 50 kg subject. 8.2 Lactation Risk Summary Sildenafil is not indicated for use in females. Limited data indicate that sildenafil and its active metabolite are present in human milk. There is no information on the effects on the breastfed child, or the effects on milk production. 8.4 Pediatric Use Sildenafil is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients. 8.5 Geriatric Use Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [ see Clinical Pharmacology (12.3) ]. Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [ see Clinical Pharmacology (12.3) ]. Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥ 65 years of age) and younger (< 65 years of age) subjects. However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure [ see Dosage and Administration (2.5) ]. 8.6 Renal Impairment No dose adjustment is required for mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment. In volunteers with severe renal impairment (Clcr<30 mL/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of C max and AUC. A starting dose of 25 mg should be considered in patients with severe renal impairment [ see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ]. 8.7 Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for C max and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [ see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ]."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Sildenafil Citrate Tablets 25 mg 72789404 Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Sildenafil was not carcinogenic when administered to rats for 24 months at a dose resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its major metabolite of 20- and 38- times, for male and female rats, respectively, the exposures observed in human males given the Maximum Recommended Human Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 10 mg/kg/day, approximately 0.4 times the MRHD on a mg/m 2 basis in a 50 kg subject. Mutagenesis Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and in vitro human lymphocytes and in vivo mouse micronucleus assays to detect clastogenicity. Impairment of Fertility There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"13046 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"12627 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"9930 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"9006 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"6858 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"6337 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"6198 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"5667 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"4876 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"4554 reports"}],"drugInteractions":[{"drug":"Nitrates (organic nitrates or organic nitrites)","severity":"Contraindicated","mechanism":"Sildenafil potentiates the hypotensive effects of nitrates through effects on the nitric oxide/cGMP pathway","management":"Contraindicated; timing for safe nitrate administration after sildenafil is unknown","clinicalEffect":"Severe hypotension"},{"drug":"Alpha-blockers","severity":"High","mechanism":"Additive blood pressure-lowering effects","management":"Use caution; patients should be stable on alpha-blocker therapy prior to initiating sildenafil; initiate sildenafil at 25 mg dose","clinicalEffect":"Hypotension"},{"drug":"Amlodipine","severity":"Moderate","mechanism":"Additive blood pressure-lowering effects","management":"Monitor blood pressure","clinicalEffect":"Mean additional reduction of 8 mmHg systolic and 7 mmHg diastolic on supine blood pressure"},{"drug":"Ritonavir (strong CYP3A4 inhibitor)","severity":"High","mechanism":"CYP3A4 inhibition increases sildenafil systemic exposure (11-fold increase in AUC)","management":"Do not exceed maximum single dose of 25 mg in a 48 hour period","clinicalEffect":"Increased sildenafil exposure and adverse effects"},{"drug":"Erythromycin or strong CYP3A4 inhibitors (ketoconazole, itraconazole, saquinavir)","severity":"High","mechanism":"CYP3A4 inhibition increases sildenafil exposure","management":"Consider starting dose of 25 mg","clinicalEffect":"Increased sildenafil exposure and adverse effects"}],"commonSideEffects":[{"effect":"Headache","drugRate":"16%","studyType":"Flexible-Dose Phase II/III","placeboRate":"4%"},{"effect":"Headache","drugRate":"28%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"7%"},{"effect":"Flushing","drugRate":"10%","studyType":"Flexible-Dose Phase II/III","placeboRate":"1%"},{"effect":"Flushing","drugRate":"18%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"2%"},{"effect":"Dyspepsia","drugRate":"7%","studyType":"Flexible-Dose Phase II/III","placeboRate":"2%"},{"effect":"Dyspepsia","drugRate":"17%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"2%"},{"effect":"Nasal Congestion","drugRate":"4%","studyType":"Flexible-Dose Phase II/III","placeboRate":"2%"},{"effect":"Nasal congestion","drugRate":"9%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"2%"},{"effect":"Abnormal Vision","drugRate":"3%","studyType":"Flexible-Dose Phase II/III","placeboRate":"0%"},{"effect":"Abnormal vision","drugRate":"11%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"1%"},{"effect":"Back pain","drugRate":"2%","studyType":"Flexible-Dose Phase II/III","placeboRate":"2%"},{"effect":"Back pain","drugRate":"4%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"2%"},{"effect":"Dizziness","drugRate":"2%","studyType":"Flexible-Dose Phase II/III","placeboRate":"1%"},{"effect":"Dizziness","drugRate":"3%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"2%"},{"effect":"Rash","drugRate":"2%","studyType":"Flexible-Dose Phase II/III","placeboRate":"1%"},{"effect":"Rash","drugRate":"3%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"1%"},{"effect":"Myalgia","drugRate":"4%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"1%"},{"effect":"Nausea","drugRate":"3%","studyType":"Fixed-Dose Phase II/III (100 mg)","placeboRate":"1%"}],"contraindications":["Administration with nitric oxide donors such as organic nitrates or organic nitrites in any form","Known hypersensitivity to sildenafil or any component of the tablet","Administration with guanylate cyclase (GC) stimulators, such as riociguat"],"specialPopulations":{"Pregnancy":"Sildenafil is not indicated for use in females. There are no data with the use of sildenafil in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m2 basis. No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis.","Geriatric use":"Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years). Of the total number of subjects in clinical studies of sildenafil, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥65 years of age) and younger (<65 years of age) subjects. However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure.","Paediatric use":"Sildenafil is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients.","Renal impairment":"No dose adjustment is required for mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment. In volunteers with severe renal impairment (Clcr<30 mL/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of Cmax and AUC. A starting dose of 25 mg should be considered in patients with severe renal impairment.","Hepatic impairment":"In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for Cmax and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment."}},"trials":[],"_chembl":null,"aliases":[],"patents":[{"applNo":"N214952","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2038","territory":"US","drugProduct":true,"patentNumber":"11337979","drugSubstance":false},{"applNo":"N214952","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2038","territory":"US","drugProduct":true,"patentNumber":"11464778","drugSubstance":false},{"applNo":"N214952","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2038","territory":"US","drugProduct":true,"patentNumber":"12186321","drugSubstance":false},{"applNo":"N214952","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2038","territory":"US","drugProduct":true,"patentNumber":"11759468","drugSubstance":false},{"applNo":"N214952","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2038","territory":"US","drugProduct":true,"patentNumber":"12005062","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T11:24:30.137294","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Sildenafil Citrate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:58.739566+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:48:58.739425+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Sildenafil Citrate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:49:06.329351+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:32:32.294679+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:49:04.755482+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:48:58.811829+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:48:57.496080+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:32:32.294700+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sildenafil Citrate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:49:05.060166+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:55.748587+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:55.748614+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:49:07.087567+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Phosphodiesterase 5A inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:06.329212+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1737/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:49:05.998998+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku AE extraction","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:32:38.947188+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA209302","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:48:55.748619+00:00"}},"offLabel":[],"timeline":[{"date":"19980327","type":"positive","milestone":"FDA approval — VIATRIS","regulator":"FDA","description":""}],"_dailymed":{"setId":"fbe75c2c-0aff-9ade-e053-6394a90a1ea4","title":"SILDENAFIL CITRATE (SILDENAFIL) TABLET, FILM COATED [NUCARE PHARMACEUTICALS,INC.]"},"aiSummary":"Sildenafil is a PDE5 inhibitor indicated for erectile dysfunction treatment that works by enhancing nitric oxide effects to increase penile blood flow. The drug has moderate bioavailability (41%) with rapid absorption and approximately 4-hour half-life, primarily metabolized hepatically via CYP3A4. Major risks include severe hypotension when combined with nitrates or alpha-blockers, and increased exposure with CYP3A4 inhibitors requiring dose adjustments. Clinical use requires careful patient selection and monitoring for drug interactions, particularly with cardiovascular agents.","ecosystem":[],"mechanism":{"target":"Phosphodiesterase type 5 (PDE5)","novelty":"first-in-class","modality":"Small molecule enzyme inhibitor","drugClass":"Phosphodiesterase-5 (PDE5) inhibitor","explanation":"Sildenafil enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. During sexual stimulation, NO is released in the corpus cavernosum and activates guanylate cyclase, increasing cGMP levels. By inhibiting PDE5, sildenafil causes increased cGMP accumulation, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum and has no effect in the absence of sexual stimulation at recommended doses. In vitro studies demonstrate that sildenafil is highly selective for PDE5, with approximately 4,000-fold selectivity compared to PDE3 (involved in cardiac contractility). However, sildenafil is only about 10-fold more potent for PDE5 compared to PDE6, an enzyme found in the retina involved in the phototransduction pathway, which is thought to be the basis for color vision abnormalities.","oneSentence":"Sildenafil inhibits phosphodiesterase type 5 to increase cGMP levels, enabling smooth muscle relaxation and penile blood inflow.","technicalDetail":"Sildenafil demonstrates exceptional selectivity for PDE5 with >80-fold potency advantage over PDE1, >700-fold over PDE2/3/4/7-11, and approximately 4,000-fold selectivity versus PDE3 (cardiac contractility regulator). The 10-fold lower selectivity versus PDE6 (retinal phototransduction) accounts for observed color vision abnormalities. PDE5 inhibition in platelets, vascular smooth muscle, and other tissues contributes to additional hemodynamic effects including platelet antiaggregatory activity and peripheral vasodilation."},"_scrapedAt":"2026-03-27T23:28:19.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Sildenafil","title":"Sildenafil","extract":"Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is also sometimes used off-label for the treatment of certain symptoms in secondary Raynaud's phenomenon. It is unclear if it is effective for treating sexual dysfunction in females. It can be taken orally, intravenously, or through the sublingual route. Onset when taken orally is typically within twenty minutes and lasts for about two hours."},"commercial":{"launchDate":"1998","annualCostUS":"$180-240/month (brand); $10-30/month (generic)","currentRevenue":"$0.7B","peakSalesEstimate":"$2.0B"},"references":[],"_validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:32:40.139218+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"name":"Cialis","company":"Eli Lilly","advantage":"Longer duration of action (up to 36 hours) and can be taken daily at lower doses"},{"name":"Levitra","company":"Bayer","advantage":"Faster onset of action (15-30 minutes) and may work better for men with diabetes"},{"name":"Stendra","company":"VIVUS","advantage":"Fastest acting option (15 minutes) with fewer food interactions"},{"name":"Spedra","company":"Menarini","advantage":"Rapid onset similar to Stendra and effective at lower doses"}],"indications":{"approved":[{"name":"Impotence","diseaseId":"impotence","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary arterial hypertension","diseaseId":"pulmonary-arterial-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["generics(35)","patents(5)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03596047","phase":"NA","title":"Radial Shockwave Therapy for Erectile Dysfunction","status":"COMPLETED","sponsor":"Boston Medical Group","startDate":"2018-04-19","conditions":"Erectile Dysfunction","enrollment":80},{"nctId":"NCT07039760","phase":"EARLY_PHASE1","title":"Asciminib With or Without Sildenafil for Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Brain Tumor","enrollment":12},{"nctId":"NCT03142568","phase":"PHASE2","title":"Safety of Sildenafil in Premature Infants","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-04-02","conditions":"Bronchopulmonary Dysplasia","enrollment":109},{"nctId":"NCT07462260","phase":"PHASE2, PHASE3","title":"Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)","status":"RECRUITING","sponsor":"Sindh Institute of Cardiovascular Diseases","startDate":"2025-08-01","conditions":"Pulmonary Hypertension, Rheumatic Valvular Heart Disease","enrollment":100},{"nctId":"NCT05061368","phase":"PHASE2","title":"Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-03-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":160},{"nctId":"NCT06123156","phase":"PHASE3","title":"Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03","conditions":"Rectal Cancer","enrollment":188},{"nctId":"NCT06810284","phase":"PHASE2","title":"Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10","conditions":"Hypoxic-Ischemic Encephalopathy","enrollment":24},{"nctId":"NCT04039464","phase":"PHASE3","title":"Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-08-01","conditions":"Pediatric Pulmonary Hypertension","enrollment":28},{"nctId":"NCT07391579","phase":"PHASE4","title":"Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-12-01","conditions":"Erectile Dysfunctions","enrollment":500},{"nctId":"NCT07377084","phase":"","title":"Metabolomics of Cancers of the Upper Aerodigestive Tract","status":"RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2020-11-04","conditions":"Upper AerodigestiveTract Cancer","enrollment":250},{"nctId":"NCT04447989","phase":"PHASE2","title":"Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia","status":"COMPLETED","sponsor":"Christoph Hornik","startDate":"2021-05-27","conditions":"Bronchopulmonary Dysplasia of Newborn","enrollment":125},{"nctId":"NCT06510322","phase":"EARLY_PHASE1","title":"Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2025-03-12","conditions":"Vascular Diseases","enrollment":50},{"nctId":"NCT06954597","phase":"PHASE2","title":"Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Topadur Pharma AG","startDate":"2025-02-04","conditions":"Digital Ulcers in Systemic Sclerosis","enrollment":15},{"nctId":"NCT04481789","phase":"PHASE1","title":"Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-10-17","conditions":"Healthy Adult Subjects","enrollment":84},{"nctId":"NCT06324396","phase":"PHASE1","title":"IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease","status":"RECRUITING","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2024-03-01","conditions":"Fontan Circulation","enrollment":15},{"nctId":"NCT07302698","phase":"PHASE1","title":"PK and Onset of Hezkue Oral Sildenafil Suspension After Alcohol Consumption","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-03-15","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT07290400","phase":"PHASE2","title":"Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-04-15","conditions":"Erectile Dysfunction","enrollment":36},{"nctId":"NCT04565925","phase":"PHASE2","title":"Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2021-07-07","conditions":"Spinal Cord Injuries, Urinary Incontinence","enrollment":24},{"nctId":"NCT07117383","phase":"PHASE1","title":"Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-01","conditions":"Erectile Dysfunction","enrollment":72},{"nctId":"NCT05782244","phase":"PHASE2","title":"Sildenafil for Microvasculopathy in Chronic TBI","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-07-02","conditions":"Traumatic Brain Injury","enrollment":160},{"nctId":"NCT07245875","phase":"NA","title":"Umbilical Cord Mesenchymal Stem Cell Secretome Administration in Severe Erectile Dysfunction Non-responsive to Sildenafil","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2024-04-12","conditions":"Erectile Dysfunction, Diabetes Mellitus Type 2","enrollment":12},{"nctId":"NCT03855332","phase":"PHASE2","title":"Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-11","conditions":"Small Vessel Cerebrovascular Disease","enrollment":75},{"nctId":"NCT06872866","phase":"PHASE1","title":"The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects","status":"RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2025-04-15","conditions":"Erectile Dysfunction","enrollment":12},{"nctId":"NCT07231185","phase":"PHASE2","title":"Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-01","conditions":"Erectile Dysfunction","enrollment":200},{"nctId":"NCT06800092","phase":"PHASE2, PHASE3","title":"Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-03-15","conditions":"Cancer","enrollment":30},{"nctId":"NCT05490680","phase":"PHASE3","title":"A New Sildenafil Oral Film in Patients With Erectile Dysfunction","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2024-01-26","conditions":"Erectile Dysfunction","enrollment":488},{"nctId":"NCT04797286","phase":"PHASE2","title":"Sildenafil for Early Pulmonary Vascular Disease in Scleroderma","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2021-09-20","conditions":"Scleroderma, Mildly Elevated Pulmonary Pressures","enrollment":30},{"nctId":"NCT07177326","phase":"PHASE3","title":"Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"Erectile Dysfunction","enrollment":142},{"nctId":"NCT06522854","phase":"PHASE3","title":"Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-05-01","conditions":"Intrapartum Fetal Distress, Neonatal Asphyxia, Intrapartum Asphyxia","enrollment":""},{"nctId":"NCT06377098","phase":"PHASE3","title":"Intrapartum Sildenafil in Laboring Mothers","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-05-01","conditions":"Neonatal Asphyxia, Intrapartum Fetal Distress, Development, Infant","enrollment":""},{"nctId":"NCT05765487","phase":"PHASE1","title":"Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%","status":"COMPLETED","sponsor":"Daré Bioscience, Inc.","startDate":"2023-05-13","conditions":"Sexual Arousal Disorder","enrollment":13},{"nctId":"NCT06778330","phase":"NA","title":"The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":100},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT07135037","phase":"PHASE2","title":"Comparison Between Treatments of Oligohydramnios","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Oligohydramnios","enrollment":40},{"nctId":"NCT03945812","phase":"PHASE4","title":"Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Wael Elbanna Clinic","startDate":"2019-06-01","conditions":"Infertility, Frozen Embryo Transfer (FET)","enrollment":665},{"nctId":"NCT05039086","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-09-01","conditions":"Pulmonary Arterial Hypertension","enrollment":13021},{"nctId":"NCT04344678","phase":"NA","title":"The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT07057011","phase":"NA","title":"Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","startDate":"2025-07-01","conditions":"Premature Ejaculation","enrollment":60},{"nctId":"NCT04356716","phase":"PHASE2","title":"Sildenafil for Treatment of Choroidal Ischemia","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-11-11","conditions":"Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration","enrollment":22},{"nctId":"NCT05741229","phase":"NA","title":"The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Persistent Pulmonary Hypertension of the Newborn, Echocardiography, Respiratory Disease","enrollment":80},{"nctId":"NCT03686306","phase":"PHASE3","title":"VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rennes University Hospital","startDate":"2021-11-24","conditions":"Peripheral Artery Disease","enrollment":106},{"nctId":"NCT06715280","phase":"PHASE4","title":"Switching of Sildenafil to Riociguat in CTEPH Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-25","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":30},{"nctId":"NCT02983461","phase":"PHASE1","title":"Use of Sildenafil for Treatment of Urinary Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-03-10","conditions":"Urinary Incontinence","enrollment":24},{"nctId":"NCT02682147","phase":"PHASE4","title":"Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eric A. Hoffman","startDate":"2017-07-10","conditions":"Emphysema","enrollment":17},{"nctId":"NCT05201144","phase":"PHASE2","title":"A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-09-15","conditions":"Congenital Diaphragmatic Hernia, Pulmonary Hypertension","enrollment":40},{"nctId":"NCT04211272","phase":"PHASE1","title":"A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-01-14","conditions":"Healthy","enrollment":47},{"nctId":"NCT04538976","phase":"PHASE4","title":"Copd Exacerbation and Pulmonary Hypertension Trial","status":"COMPLETED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2020-02-01","conditions":"Acute Exacerbation of COPD","enrollment":250},{"nctId":"NCT06875258","phase":"PHASE4","title":"PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-15","conditions":"Erectile Dysfunction Following Radical Prostatectomy","enrollment":198},{"nctId":"NCT06860399","phase":"PHASE1, PHASE2","title":"Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn","status":"COMPLETED","sponsor":"Damascus University","startDate":"2023-05-01","conditions":"PPHN","enrollment":55},{"nctId":"NCT06839651","phase":"PHASE1","title":"Umbilical Cord Mesenchymal Stem Cell Secretome in Severe Erectile Dysfunction Non-responsive to Sildenafil","status":"NOT_YET_RECRUITING","sponsor":"Indonesia University","startDate":"2025-04-21","conditions":"Erectile Dysfunctions","enrollment":10},{"nctId":"NCT03382106","phase":"PHASE4","title":"Smoking Cessation and Functional CT Assessment","status":"COMPLETED","sponsor":"Eric A. Hoffman","startDate":"2018-03-19","conditions":"Emphysema","enrollment":162},{"nctId":"NCT06649539","phase":"PHASE4","title":"Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease","status":"RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2024-10-11","conditions":"Peyronie Disease","enrollment":40},{"nctId":"NCT06178523","phase":"PHASE4","title":"Cost-effective Treatment of Unexplained Infertility","status":"COMPLETED","sponsor":"Batterjee Medical College","startDate":"2024-01-01","conditions":"Unexplained Infertility","enrollment":900},{"nctId":"NCT00433329","phase":"PHASE4","title":"Combination Therapy in Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2007-03","conditions":"Pulmonary Arterial Hypertension","enrollment":100},{"nctId":"NCT00303459","phase":"PHASE4","title":"Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2006-05","conditions":"Pulmonary Arterial Hypertension","enrollment":334},{"nctId":"NCT00302211","phase":"PHASE3","title":"The \"VISION\" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2006-02-01","conditions":"Pulmonary Hypertension","enrollment":67},{"nctId":"NCT06797479","phase":"","title":"Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-03-01","conditions":"Gynecological Cancer, Immunotherapy","enrollment":12},{"nctId":"NCT06782659","phase":"PHASE1","title":"Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2025-01","conditions":"Erectile Dysfunction","enrollment":56},{"nctId":"NCT06098833","phase":"PHASE2","title":"Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia","status":"RECRUITING","sponsor":"Pia Wintermark","startDate":"2024-07-01","conditions":"Neonatal Encephalopathy","enrollment":60},{"nctId":"NCT06753981","phase":"","title":"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-12-10","conditions":"Arterial Pulmonary Hypertension (PAH)","enrollment":48},{"nctId":"NCT05275725","phase":"PHASE1","title":"Finding Solutions to Thrive After Birth Asphyxia in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pia Wintermark","startDate":"2022-07-01","conditions":"Birth Asphyxia","enrollment":18},{"nctId":"NCT04912726","phase":"NA","title":"Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension","status":"WITHDRAWN","sponsor":"Universidad del Norte","startDate":"2025-01-01","conditions":"Hypertension, Pulmonary","enrollment":""},{"nctId":"NCT05196308","phase":"PHASE2","title":"Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-18","conditions":"Erectile Dysfunction","enrollment":226},{"nctId":"NCT04898114","phase":"PHASE1, PHASE2","title":"Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn","status":"RECRUITING","sponsor":"Sohag University","startDate":"2021-06-02","conditions":"Persistent Pulmonary Hypertension of Newborn","enrollment":40},{"nctId":"NCT06058832","phase":"NA","title":"Effects of Low-intensity Shockwave Therapy Versus Kegel Exercises on Arteriogenic Erectile Dysfunction in DM Patients","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-01-05","conditions":"Sexual Dysfunction, Shock Wave","enrollment":90},{"nctId":"NCT04985929","phase":"PHASE2","title":"The Impact of Sildenafil on the Pulmonary Circulation in Healthy Trained and Untrained Humans","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-07-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT04039087","phase":"PHASE2, PHASE3","title":"Sildenafil Exercise: Role of PDE5 Inhibition","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":26},{"nctId":"NCT06562036","phase":"NA","title":"Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2023-12-01","conditions":"Persistent Pulmonary Hypertension of the Newborn","enrollment":42},{"nctId":"NCT06565728","phase":"PHASE1","title":"Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-11-03","conditions":"Fetal Growth Retardation","enrollment":99},{"nctId":"NCT06527729","phase":"EARLY_PHASE1","title":"A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-07-01","conditions":"Alopecia Areata","enrollment":28},{"nctId":"NCT01817751","phase":"PHASE2","title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-04-11","conditions":"Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma","enrollment":47},{"nctId":"NCT04169191","phase":"PHASE1","title":"Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia","status":"ACTIVE_NOT_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-09-19","conditions":"Birth Asphyxia","enrollment":20},{"nctId":"NCT03199612","phase":"EARLY_PHASE1","title":"Sildenafil To Prevent Clot","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2019-06-03","conditions":"Thrombosis, Hemolysis","enrollment":20},{"nctId":"NCT06237751","phase":"NA","title":"Preoperative Sildenafil Administration for Hepatectomy","status":"RECRUITING","sponsor":"First People's Hospital of Chenzhou","startDate":"2024-02-01","conditions":"Central Venous Pressure, Hepatectomy, Hemodynamics Instability","enrollment":16},{"nctId":"NCT04122105","phase":"NA","title":"PDE5i Use in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2021-04-01","conditions":"Renal Transplant Failure","enrollment":""},{"nctId":"NCT05946681","phase":"","title":"Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings","status":"COMPLETED","sponsor":"NICHD Global Network for Women's and Children's Health","startDate":"2023-05-16","conditions":"Fetal Distress, Perinatal Asphyxia, Birth Asphyxia","enrollment":1017},{"nctId":"NCT02421068","phase":"","title":"Population PK/PD of Off Label Drugs in Premature Neonates","status":"COMPLETED","sponsor":"Sinno H.P. Simons","startDate":"2014-08","conditions":"Premature Birth","enrollment":246},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":"Pulmonary Arterial Hypertension","enrollment":110},{"nctId":"NCT06289881","phase":"PHASE1","title":"Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2025-02-04","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT04058132","phase":"PHASE2","title":"Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military","status":"TERMINATED","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2019-08-09","conditions":"Traumatic Brain Injury","enrollment":1},{"nctId":"NCT02284737","phase":"PHASE4","title":"A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH","status":"TERMINATED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2014-11-28","conditions":"Pulmonary Arterial Hypertension","enrollment":100},{"nctId":"NCT04770155","phase":"EARLY_PHASE1","title":"Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1","status":"TERMINATED","sponsor":"University of Mississippi Medical Center","startDate":"2021-05-27","conditions":"Vascular Function, Racial Disparity","enrollment":8},{"nctId":"NCT05889455","phase":"NA","title":"Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-04-20","conditions":"Migraine Without Aura","enrollment":16},{"nctId":"NCT06064448","phase":"PHASE4","title":"Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction","status":"COMPLETED","sponsor":"Xintian Pharmaceutical","startDate":"2019-03-19","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Erectile Dysfunction","enrollment":254},{"nctId":"NCT05684289","phase":"PHASE1","title":"A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-03","conditions":"Healthy Participants","enrollment":61},{"nctId":"NCT00871065","phase":"PHASE2","title":"Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-07","conditions":"Cerebral Vasospasm, Subarachnoid Hemorrhage","enrollment":""},{"nctId":"NCT03945643","phase":"EARLY_PHASE1","title":"Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?","status":"COMPLETED","sponsor":"University of Oregon","startDate":"2019-07-01","conditions":"Patent Foramen Ovale, Intrapulmonary Arteriovenous Anastamosis","enrollment":82},{"nctId":"NCT05971667","phase":"PHASE2, PHASE3","title":"Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-30","conditions":"IVF","enrollment":200},{"nctId":"NCT05951413","phase":"PHASE2, PHASE3","title":"The Effect of Sildenafil Citrate on Frozen Embryo Transfer Cycles","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-06-30","conditions":"IVF","enrollment":110},{"nctId":"NCT00793338","phase":"PHASE4","title":"Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2008-11","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT04706546","phase":"NA","title":"Hemodynamic Effects During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Hypertension, Pulmonary","enrollment":24},{"nctId":"NCT04704440","phase":"NA","title":"Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Hypertension, Pulmonary","enrollment":24},{"nctId":"NCT04697862","phase":"NA","title":"Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Hypertension, Pulmonary","enrollment":24},{"nctId":"NCT04715113","phase":"NA","title":"Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Hypertension, Pulmonary","enrollment":24},{"nctId":"NCT05846906","phase":"PHASE2, PHASE3","title":"Effect of Oral Sildenafil Citrate on Improvement of Endometrial Thickness","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-10-01","conditions":"Infertility, Female","enrollment":130},{"nctId":"NCT03997097","phase":"PHASE3","title":"Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease","status":"WITHDRAWN","sponsor":"University Hospital, Montpellier","startDate":"2023-06-01","conditions":"Single-ventricle, Pulmonary Hypertension, Univentricular Heart","enrollment":""},{"nctId":"NCT05753098","phase":"PHASE4","title":"Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy for Unexplained Infertility","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-01-15","conditions":"Subfertility, Female","enrollment":148},{"nctId":"NCT05546125","phase":"","title":"a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China","status":"COMPLETED","sponsor":"Pfizer Pharmaceuticals Ltd.","startDate":"2021-12-23","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":100},{"nctId":"NCT05669885","phase":"NA","title":"Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache","status":"UNKNOWN","sponsor":"Danish Headache Center","startDate":"2023-01-02","conditions":"Post-Traumatic Headache","enrollment":21},{"nctId":"NCT04325243","phase":"PHASE4","title":"Sildenafil Citrate and Intrapartum Fetal Distress","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-09-01","conditions":"Fetal Distress","enrollment":410}],"_emaApprovals":[{"name":"Viagra","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":9186,"reaction":"DRUG INEFFECTIVE"},{"count":2980,"reaction":"ERECTION INCREASED"},{"count":1899,"reaction":"HEADACHE"},{"count":1252,"reaction":"MALIGNANT MELANOMA"},{"count":1203,"reaction":"ERECTILE DYSFUNCTION"},{"count":870,"reaction":"DIZZINESS"},{"count":863,"reaction":"FATIGUE"},{"count":859,"reaction":"DEATH"},{"count":853,"reaction":"EJACULATION DISORDER"},{"count":849,"reaction":"PAIN"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1737"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"tmax":"30 to 120 minutes (median 60 minutes) in fasted state; delayed 60 minutes with high fat meal","halfLife":"approximately 4 hours","clearance":"predominantly by hepatic metabolism via CYP3A4 (major route) and CYP2C9 (minor route)","excretion":"approximately 80% of administered oral dose in feces; approximately 13% in urine","metabolism":"N-desmethylation of sildenafil via CYP3A4 and CYP2C9; major metabolite has PDE5 potency approximately 50% of parent drug","proteinBinding":"approximately 96% bound to plasma proteins","bioavailability":"41% (range 25-63%)","volumeOfDistribution":"105 L (mean steady state)"},"publicationCount":1403,"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":35,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Grp Ptc","Ajanta Pharma Ltd","Alkem Labs Ltd","Amneal Pharms","Amneal Pharms Ny","Apotex Corp","Appco","Aurobindo Pharma Ltd","Cadila Pharms Ltd","Chartwell Rx","Eugia Pharma","Granules","Hetero Labs Ltd V","Invagen Pharms","Jubilant Generics","Lupin Ltd","Macleods Pharms Ltd","Msn","Mylan","Mylan Pharms Inc","Novitium Pharma","Perrigo R And D","Reyoung","Rubicon Research","Sunshine","Taro","Teva","Teva Pharms","Teva Pharms Usa","Torrent","Torrent Pharms Ltd","Tris Pharma Inc","Umedica","Watson Labs Inc","Zydus Lifesciences"],"phase":"marketed","status":"approved","brandName":"Viagra","genericName":"Sildenafil Citrate","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1998","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-11-19T00:00:00.000Z","mah":"VIATRIS","brand_name_local":null,"application_number":"NDA022473"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-02-08T00:00:00.000Z","mah":"MSN","brand_name_local":null,"application_number":"ANDA214641"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-08-29T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":null,"application_number":"ANDA216383"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-08T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":null,"application_number":"ANDA212260"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-12-16T00:00:00.000Z","mah":"IBSA","brand_name_local":null,"application_number":"NDA210858"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":20,"withResults":3},"validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:32:40.139218+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}